University of Tennessee Cancer Institute SC-2 — Memphis, Tennessee

University of Tennessee Cancer Institute SC-2 is a clinical research site located in Memphis, Tennessee, United States 38104.

Crixeo Health Trust Score: 56/100 (POOR). This profile has not yet been claimed by the site owner.

University of Tennessee Cancer Institute SC-2 has participated in 2 clinical trials.

Therapeutic areas: Diffuse Large B-cell Lymphoma, Relapsed or Refractory Multiple Myeloma.

Sponsors: Novartis Pharmaceuticals.

Sponsor Feasibility Report

Trust Score: 56/100. Verification status: Not yet accredited. Patient reviews: 0. Complaints: 0.

Frequently Asked Questions

What is the Trust Score for University of Tennessee Cancer Institute SC-2?

University of Tennessee Cancer Institute SC-2 has a Crixeo Trust Score of 56/100 (POOR). Trust Scores reflect trial volume, sponsor diversity, patient reviews, address verification, and accreditation status.

How many clinical trials has University of Tennessee Cancer Institute SC-2 conducted?

University of Tennessee Cancer Institute SC-2 has 2 clinical trials on record. Their work covers Diffuse Large B-cell Lymphoma, Relapsed or Refractory Multiple Myeloma.

Is University of Tennessee Cancer Institute SC-2 accredited by Crixeo Health?

University of Tennessee Cancer Institute SC-2 has not yet obtained Crixeo Accreditation. Site owners can claim their profile and apply for accreditation to improve visibility with sponsors and patients.

Can I submit a review or complaint about University of Tennessee Cancer Institute SC-2?

Yes. Patients and trial participants can submit reviews and file complaints directly on this profile page. All submissions are reviewed before publication.